Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy

Documenti analoghi

• Targeting HIF as a Promising Approach to Synergize With Immune Checkpoint Inhibitors
  di: Shuai Li, et al.
  Pubblicazione: (2026)
• Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non‐Small Cell Lung Cancer
  di: Shouzheng Wang, et al.
  Pubblicazione: (2025)
• The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis
  di: Xu Tong, et al.
  Pubblicazione: (2026)
• Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
  di: Ling Chen, et al.
  Pubblicazione: (2024)
• Associations Between Pre‐Existing Cardiovascular Disease and Survival in Patients on Immune Checkpoint Inhibitor Therapy
  di: Aditya Mahadevan, et al.
  Pubblicazione: (2025)